Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06699940 · ClinicalTrials.gov registry record
A Retrospective Study to Evaluate NeuroStar® Advanced Therapy in Adolescents
A clinical trial, sponsored by Neuronetics.
- Completed
- Registry status
- 7,690
- Enrollment target
NCT06699940: Completed study, sponsored by Neuronetics.
NCT06699940 is a clinical trial that has completed, run by Neuronetics. The registered enrollment target is 7,690 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06699940 has completed, sponsored by Neuronetics.
- COMPLETED
- Registry status
- 7,690 participants
- Enrollment target
Study Summary
To assess the real-world effectiveness of transcranial magnetic stimulation (TMS) for depression in large adolescent and young adult samples.
Primary Outcome
To assess the pre-treatment to post-treatment change in PHQ-9 scores for the adolescent patient population. PHQ-9 is the Patient Health Questionnaire is a 9-question patient-completed assessment. Total scores range from 0 to 27. Higher the score means higher the depression severity.
Interventions
- DEVICE Transcranial Magnetic Stimulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,690 participants |
| Start Date | 2023-05-01 |
| Est. Completion | 2023-05-01 |
What the finished NCT06699940 record still lists
NCT06699940 is an observational study that tracks outcomes without assigning an intervention. Its 7,690 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Transcranial Magnetic Stimulation is the first listed.
NCT06699940 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06699940 about?
NCT06699940 is a clinical study titled "A Retrospective Study to Evaluate NeuroStar® Advanced Therapy in Adolescents". To assess the real-world effectiveness of transcranial magnetic stimulation (TMS) for depression in large adolescent and young adult samples.
What is the current status of trial NCT06699940?
This trial is currently completed. The enrollment target is 7,690 participants. The study started on 2023-05-01. Estimated completion is 2023-05-01.
What interventions are being tested in trial NCT06699940?
The interventions under investigation include: Transcranial Magnetic Stimulation (DEVICE).
Who is sponsoring clinical trial NCT06699940?
This trial is sponsored by Neuronetics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06560398 · 7,649 participants · NA
Working Through Outreach, Navigation and Digital Enabled Referral and Recruitment Strategies (ACT WONDER²S)
- NCT03848312 · 7,600 participants · Phase 3
Preventing Alzheimer's With Cognitive Training
- NCT00439049 · 7,500 participants
Substance Abuse Pre-Treatment Screening Study
- NCT04809740 · 7,500 participants · NA
Evaluating the Implementation and Impact of Navigator-delivered ePRO System
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI